高级检索
颜幸杰, 李柳梅, 陈玉娟, 林丽群, 潘思强. 参芪三甲汤联合经肝动脉插管化疗栓塞术对原发性肝癌患者相关指标及Child-Pugh分级的影响[J]. 实用临床医药杂志, 2023, 27(10): 46-50. DOI: 10.7619/jcmp.20230808
引用本文: 颜幸杰, 李柳梅, 陈玉娟, 林丽群, 潘思强. 参芪三甲汤联合经肝动脉插管化疗栓塞术对原发性肝癌患者相关指标及Child-Pugh分级的影响[J]. 实用临床医药杂志, 2023, 27(10): 46-50. DOI: 10.7619/jcmp.20230808
shu
YAN Xingjie, LI Liumei, CHEN Yujuan, LIN Liqun, PAN Siqiang. Effect of Shenqi Sanjia Decoction combined with transcatheter arterial chemoembolization on related indexes and Child-Pugh classification of patients with primary liver cancer[J]. Journal of Clinical Medicine in Practice, 2023, 27(10): 46-50. DOI: 10.7619/jcmp.20230808
Citation: YAN Xingjie, LI Liumei, CHEN Yujuan, LIN Liqun, PAN Siqiang. Effect of Shenqi Sanjia Decoction combined with transcatheter arterial chemoembolization on related indexes and Child-Pugh classification of patients with primary liver cancer[J]. Journal of Clinical Medicine in Practice, 2023, 27(10): 46-50. DOI: 10.7619/jcmp.20230808
shu

参芪三甲汤联合经肝动脉插管化疗栓塞术对原发性肝癌患者相关指标及Child-Pugh分级的影响

Effect of Shenqi Sanjia Decoction combined with transcatheter arterial chemoembolization on related indexes and Child-Pugh classification of patients with primary liver cancer

    摘要
  • 摘要:
    目的 探讨参芪三甲汤联合经肝动脉插管化疗栓塞术(TACE)对原发性肝癌患者血清甲胎蛋白异质体L3(AFP-L3)、高尔基体糖蛋白-73(GP-73)、磷脂酰肌醇蛋白聚糖-3(GPC-3)及Child-Pugh分级的影响。
    方法 选取62例原发性肝癌患者为研究对象，随机分为对照组(给予TACE治疗)与观察组(给予TACE联合参芪三甲汤治疗)，每组31例。比较2组总有效率、中医证候积分(胸闷气短、疲倦乏力、面色淡白、头晕目眩)、肝功能、Child-Pugh分级、AFP-L3、GP-73、GPC-3、疾病进展(PD)发生率及无进展生存期。
    结果 观察组总有效率为93.55%, 高于对照组的74.19%, 差异有统计学意义(P < 0.05)。治疗后，观察组的中医证候积分、γ-谷氨酰基转移酶(GGT)、丙氨酸氨基转移酶(ALT)、总胆红素(TBil)、天门冬氨酸氨基转移酶(AST)、AFP-L3、GP-73、GPC-3低于对照组，差异有统计学意义(P < 0.05)。观察组治疗后Child-Pugh分级优于对照组，差异有统计学意义(P < 0.05)。观察组PD发生率低于对照组，无进展生存期长于对照组，差异有统计学意义(P < 0.05)。
    结论 参芪三甲汤联合TACE治疗原发性肝癌可改善肝功能，降低AFP-L3、GP-73、GPC-3表达水平。

     

    Abstract:
    Objective To explore the effect of Shenqi Sanjia Decoction combined with transcatheter arterial chemoembolization (TACE) on serum levels of alpha-fetoprotein isoplast L3 (AFP-L3), Golgi glycoprotein-73 (GP-73) and phosphatidyl inositol proteosan-3 (GPC-3) as well as Child-Pugh classification in patients with primary liver cancer.
    Methods A total of 62 patients with primary liver cancer were selected as research objects, and they were randomly divided into control group (treated with TACE) and observation group (treated with Shenqi Sanjia Decoction and TACE), with 31 cases in each group. Total effective rate, score of tradition Chinses medicine syndrome (chest tightness and shortness of breath, fatigue and weak, pale complexion, and dizziness and vertigo), liver function, Child-Pugh classification, AFP-L3, GP-73, GPC-3, incidence of disease progression (PD) and progression free survival were compared between two groups.
    Results The total effective rate of the observation group was 93.55%, which was significantly higher than 74.19% of the control group (P < 0.05). After treatment, the score of traditional Chinses medicine syndrome, γ-glutamyl transferase (GGT), alanine aminotransferase (ALT), total bilirubin (TBil), aspartate aminotransferase(AST), AFP-L3, GP-73 and GPC-3 in the observation group were significantly lower than those in the control group (P < 0.05). After treatment, the Child-Pugh classification in the observation group was significantly better than that in the control group (P < 0.05). The incidence of PD in the observation group was significantly lower than that in the control group, while the progression free survival was significantly longer than that in the control group (P < 0.05).
    Conclusion Shenqi Sanjia Decoction combined with TACE can improve liver function and reduce the expression levels of AFP-L3, GP-73 and GPC-3 in patients with primary liver cancer.

     

    • HTML全文
    • 参考文献(18)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回